Incyte Stock News

Related Stocks: IDXX , SRPT , MOH , ZTS , AZN , LH , MRNA , GH , ICLR , JAZZ , RLYB , FUSN , VRTX , AMED , ALXN , CNC , INCY , IOVA ,

VANCOUVER, BC , Dec. 8, 2021 /PRNewswire/ -- USA News Group - Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics . Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis . Last December, biotechs working on breast cancer treatments saw their shares soar . This year has continued that momentum, with multiple biotech companies driving progress in the fight against cancer, including from Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ), Incyte Corporation (NASDAQ: INCY ), BriaCell Therapeutics Corp. (NASDAQ: BCTX ), Gilead Sciences, Inc. (NASDAQ: GILD ), and Eli Lilly and Company (NYSE: LLY ). Coming up between December 11-14, 2021 , Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ) will give an update at the upcoming 63 rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) on its Phase II Triple-Negative Breast Cancer Trial—known as the IRENE study, which is evaluating the company''s flagship product pelareorep, an immunotherapeutic agent that turns "cold" tumors "hot", in combination with the anti-PD-1 checkpoint inhibitor, retifanlimab, from Incyte Corporation (NASDAQ: INCY ).

SAN FRANCISCO and SUZHOU, China , Dec. 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that results of a phase 1 clinical trial of IBI362 (LY3305677), a dual glucagon-like petide-1 (GLP-1) and glucagon receptor agonist in patients with type 2 diabetes are presented as an e-poster at the International Diabetes Federation Congress 2021. This randomized, double-blind, placebo-controlled multiple-ascending-dose phase 1b study evaluated the safety, tolerability and pharmacokinetics/ pharmacodynamics of IBI362 in Chinese patients with type 2 diabetes, with dulaglutide as an active control. Fourteen patients were enrolled in each of the three cohorts and randomized 8:4:2 to receive once weekly IBI362, placebo or 1.5 mg dulaglutide subcutaneously for 12 weeks. Dose escalation regimens for IBI362 and placebo were 1.0-2.0-3.0 mg (cohort 1), 1.5-3.0-4.5 mg (cohort 2) or 2.0-4.0-6.0 mg (cohort 3), with each dose level administered for 4 weeks.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ: MRUS ) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors. The e-poster will be presented at the ESMO Immuno-Oncology (ESMO IO) Congress 2021 being held December 8-11, 2021 in Geneva, Switzerland. Presentation Details: Title: Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors Poster #: 136P The e-poster will be available on the virtual platform, in the e-poster section as of Monday, December 6 at 6:00 am ET and on-site at the e-Poster stations starting on Wednesday, December 8. The poster will also be available on the Merus website .

Incyte (NASDAQ:INCY) and Zymergen (NASDAQ:ZY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability. Analyst Ratings This is a summary of current ratings and price targets for Incyte and Zymergen, as reported []

Incyte Co. (NASDAQ:INCY) has been assigned an average rating of Buy from the thirteen brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The average 12 month target []

Brokerages expect Incyte Co. (NASDAQ:INCY) to report sales of $826.27 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Incytes earnings, with estimates ranging from $789.24 million to $878.83 million. Incyte posted sales of $789.51 million during the same quarter last year, which would indicate a positive year over []

MorphoSys AG found using ticker (MOR) now have 2 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 21.86 and 11.92 calculating the mean target price we have 16.89. Given that the stocks previous close was at 9.72 this indicates there is a potential upside of 73.8%. The 50 day moving average now sits at 11.49 and the 200 day MA is 17.78. The company has a market cap of $1,411m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="MOR" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.

Incyte Co. (NASDAQ:INCY) has been assigned an average rating of Buy from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average 12 []

SAN FRANCISCO and SUZHOU, China , Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces the Company''s stock is included in the Hang Seng China Enterprises Index (HSCEI) according to the Hang Seng Indexes Company''s latest results of review. The inclusion will take effect on December 6, 2021 . The HSCEI is one of the most influential indexes in the Hong Kong and global stock markets, as constituted by 50 leading China enterprises listed on the Hong Kong Stock Exchanges with outstanding market cap and trading volume. Innovent is the first and only biopharmaceutical company listed under Chapter 18A of the Hong Kong Stock Exchanges to be included in the HSCEI, and the inclusion could indicate potential additional capital inflow from passive index funds. Mr. Ronald Ede , Executive Director and CFO of Innovent, stated, "We are excited that our stock is included into the HSCEI, following the successful inclusion in the Hang Seng Composite Index and the Stock Connect last year.

BMO Capital Markets initiated coverage on shares of Incyte (NASDAQ:INCY) in a research note released on Thursday, Price Targets.com reports. The firm issued a market perform rating and a $75.00 price objective on the biopharmaceutical companys stock. INCY has been the topic of several other research reports. Royal Bank of Canada dropped their target price []

Equities research analysts at BMO Capital Markets started coverage on shares of Incyte (NASDAQ:INCY) in a note issued to investors on Thursday, The Fly reports. The brokerage set a market perform rating on the biopharmaceutical companys stock. INCY has been the topic of several other research reports. Royal Bank of Canada lowered their target price []

NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that Mary Crowley Cancer Research center in Dallas, Texas is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCells lead candidate, Bria-IMT, with Incytes checkpoint inhibitors, retifanlimab and epacadostat.

Walleye Capital LLC cut its holdings in Incyte Co. (NASDAQ:INCY) by 14.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,230 shares of the biopharmaceutical companys stock after selling 530 shares during the period. Walleye Capital LLCs holdings in Incyte were worth $272,000 as of its []